从全基因组关联研究到在炎症性关节炎中合理优先考虑药物标
Hai Fang1, Liye Chen2, Julian C Knight1
1Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
The Lancet. Rheumatology
|January 23, 2024
概括
对炎症性关节炎的基因验证药物标的识别至关重要,但具有挑战性. 将遗传变异与核心和外围基因联系起来的新方法可以改善这些疾病的药物标发现和验证.
科学领域:
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 全基因组关联研究 (GWAS) 已经确定了炎症性关节炎的众多遗传关联.
- 从历史上看,将这些遗传发现转化为针对炎症性关节炎的验证药物标是很糟糕的.
- 现有的药物开发工作,如阿巴塔塞普和塞库金纳姆,显示部分成功,但突出未满足的需求.
研究的目的:
- 探索新的策略,以提高GWAS在识别和验证炎症性关节炎的药物标中的实用性.
- 解决将遗传关联转化为治疗炎症性关节炎的成功药物开发的障碍.
- 利用功能性基因组学和网络信息来改善药物向发现.
主要方法:
- 策划81个高质量的GWAS与炎症性关节炎相关的数据集.
- 利用功能性基因组学将遗传变异与核心基因联系起来.
- 使用网络信息来识别相互连接的外围基因.
- 分析生物途径交叉对治疗干预点的分析.
主要成果:
- 虽然没有任何遗传发现完全推动了药物开发,但对于类风湿性关节炎和结性脊柱炎存在部分成功.
- 在理解遗传架构,监管机制和目标可处理性方面仍然存在挑战.
- 新兴的机会包括整合功能基因组学和网络分析.
结论:
- 整合功能基因组学和网络分析的新方法可以最大限度地提高GWAS在炎症性关节炎中药物标验证的信息性.
- 识别生物学途径交叉的关键点为治疗干预提供了有前途的途径.
- 需要改进的方法来克服目前在将遗传发现转化为炎症性关节炎的有效治疗方法方面的局限性.
相关概念视频
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


